173 related articles for article (PubMed ID: 30578575)
1. Aquagenic pruritus and the JAK2 V617F mutation.
Langabeer SE
Clin Exp Dermatol; 2019 Apr; 44(3):e33. PubMed ID: 30578575
[No Abstract] [Full Text] [Related]
2. An increase in diagnostic JAK2 V617F mutation testing: Is masked polycythaemia vera the explanantion?
Langabeer SE
Eur J Intern Med; 2018 Jun; 52():e37-e38. PubMed ID: 29622375
[No Abstract] [Full Text] [Related]
3. [Not Available].
Bächli E; Gundelfinger M
Praxis (Bern 1994); 2017 Jul; 106(15):807-813. PubMed ID: 28745110
[No Abstract] [Full Text] [Related]
4. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center.
Davila-Gonzalez D; Barrios-Ruiz A; Fountain E; Cheng L; Masarova L; Verstovsek S; Rojas-Hernandez CM
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):224-229. PubMed ID: 33349602
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms].
Kerguelén Fuentes AE; Hernández-Maraver D; Lombardia L; Canales Albendea MA; Rodriguez de la Rúa A
Med Clin (Barc); 2012 Oct; 139(9):373-8. PubMed ID: 22743278
[TBL] [Abstract][Full Text] [Related]
7. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
8. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
9. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
10. Straightforward identification of masked polycythemia vera based on proposed revision of World Health Organization diagnostic criteria for BCR-ABL1-negative myeloproliferative neoplasms.
Chu D; Cho YU; Jang S; Seo EJ; Park CJ
Ann Lab Med; 2015 Nov; 35(6):651-3. PubMed ID: 26354357
[No Abstract] [Full Text] [Related]
11. The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera.
Pieri L; Bogani C; Guglielmelli P; Zingariello M; Rana RA; Bartalucci N; Bosi A; Vannucchi AM
Haematologica; 2009 Nov; 94(11):1537-45. PubMed ID: 19608683
[TBL] [Abstract][Full Text] [Related]
12. Low frequency of JAK2 exon 12 mutations in classic and atypical CMPDs.
Ormazábal C; Hurtado C; Aranaz P; Erquiaga I; García-Delgado M; Calasanz MJ; Novo FJ; Vizmanos JL
Leuk Res; 2008 Sep; 32(9):1485-7. PubMed ID: 18291525
[No Abstract] [Full Text] [Related]
13. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
14. Characterization of murine JAK2V617F-positive myeloproliferative disease.
Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study.
Tondeur S; Paul F; Riou J; Mansier O; Ranta D; Le Clech L; Lippert E; Tavitian S; Chaoui D; Mercier M; De Renzis B; Cottin L; Cassinat B; Chrétien JM; Ianotto JC; Allangba O; Marzac C; Voillat L; Boyer F; Orvain C; Hunault-Berger M; Girodon F; Kiladjian JJ; Ugo V; Luque Paz D
Leukemia; 2021 Mar; 35(3):871-875. PubMed ID: 32694617
[No Abstract] [Full Text] [Related]
16. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
17. The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.
Ancochea A; Alvarez-Larrán A; Morales-Indiano C; García-Pallarols F; Martínez-Avilés L; Angona A; Senín A; Bellosillo B; Besses C
Br J Haematol; 2014 Nov; 167(3):411-7. PubMed ID: 25040297
[TBL] [Abstract][Full Text] [Related]
18. Splenomegaly and the JAK2 V617F mutation.
Langabeer SE
Eur J Intern Med; 2017 Jan; 37():e45-e46. PubMed ID: 27727073
[No Abstract] [Full Text] [Related]
19. Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.
Hsu HC
J Chin Med Assoc; 2007 Mar; 70(3):89-93. PubMed ID: 17389152
[TBL] [Abstract][Full Text] [Related]
20. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.
Vainchenker W; Constantinescu SN
Hematology Am Soc Hematol Educ Program; 2005; ():195-200. PubMed ID: 16304380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]